MULTI CANCER EARLY DETECTION GeneseeqMCED (CanScan™) Multi-cancer Early Detection About GeneseeqMCED GeneseeqMCED(CanScan™) is a CE-marked, liquid biopsy and NGS based, multi-cancer early detection test. With a single tube of blood, our test offers the non-invasive solution for detecting and managing cancer early, thereby improving survival. KEY FEATURES Single blood draw Detect Cancer Signals BREAKTHROUGH DEVICE DESIGNATION Across 9 Cancer Classes Includes 21 AJCC*Cancer Types which contribute to 57.0% new incidence and 63.6% mortality globally Intestine Liver Prostate Endometrium Breast Prostate Stomach Endometrium Stomach Esophagus Pancreas Pancreas Liver Esophagus Highly Sensitive Technology *Data source:Globocan 2022 FDA Breakthrough Device Designation Granted Who is it for Cancer signals Tissue of origin Sample Receipt Recommended for individuals at average Next Generation Sequencing Follow-up diagnostic tests or high risk of cancer above 45 years old. Intended to use together with routine Sample Preparation Clinical Reports physical exams, once per year. Bioinformatic Analysis Identify the tissue of origin (TOO) Clinical diagnosis & treatment planning Regular Screening Limit of use: Not recommended for individuals who are pregnant, diagnosed with cancer in the past three years, or undergoing active cancer treatment. Copyright © 2025. GENESEEQ Technology Inc. All rights reser

MULTI CANCER EARLY DETECTION Why Using CanScan™ in the Clinic 5-year survival rate of advanced-stage cancer 59% of cancer deaths are caused by cancers not commonly screened for 5-year survival rate of early-stage cancer Over50 Cancers Data source: SEER, USPSTF have no recommended screening 5 cancer types with USPSTF screening recommendations include: lung, breast, colorectal, prostate and cervical cancer. Technologies for Early Cancer Detection of cancer patients who were missed by screening can be detected by a CanScan™ test. 85% cancers detectable by CanScan™ cover 85% of new cancer cases....

MULTI CANCER EARLY DETECTION CanScan™ Key Advantages Technology Innovation Cutting-edge _^tercury Technology Highly Sensitive Performance Plasma cfDNA low-depth WGS Cancer status Tumor cells Plasma cfDNA Fragment Size Genome-wide Multidimensional Features AI Model with Big Data Gene Expression case-control study* Validated by Clinical Studies Peer-reviewed Top Publications to Date DECIPHER-Omnia Study Published in Nature Medicine* 60,000+ liquid biopsy samples 48+ clinical projects in translational research 250+ journal impact factor DECIPHER-GC, Genome Medicine (IF = 10.4) • DEC • DECIPHER-Multi,...

MULTI CANCER EARLY DETECTION Expert highlights as "a true tour de force" Nature Medicine published Research Briefing "AI-powered fragmentomics of cell-free DNA for early detection of multiple cancers" acclaiming CanScan™ technological promise and clinical value: This work provides an invaluable dataset and baseline for future MCED development. View the experts and editors´ opinion EXPERT OPINION The study is a true tour de force, generating WGS data of plasma cfDNA from over 3,600 patients, 4,000 controls and 3,700 participants in a prospective screening program. FROM THE EDITOR This research...